Journal article

Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry

Yadanar Lwin, Glenn Kennedy, David Gottlieb, John Kwan, David Ritchie, Jeff Szer, Samuel Milliken, Peter Browett, Andrew Spencer, Andrew Butler, Peter Bardy, Matthew Greenwood, Travis Perera, Simon He, Ashley McEwan, Stephen Larsen, Hock Lai, Duncan Purtill, Steven Tran, Donna Aarons Show all

Biology of Blood and Marrow Transplantation | ELSEVIER SCIENCE INC | Published : 2020


To review the updated trends of national practice and outcomes in transplantation to treat myelofibrosis (MF), we retrospectively evaluated 142 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) for primary (n = 94) or secondary (n = 48) MF at an Australian/New Zealand transplantation center between 2006 and 2017. The median duration of follow-up was 51.8 months (range, 3.1 to 148 months). The median age at allo-HSCT was 56 years (range, 26 to 69 years). Fifty-two percent of the patients had HLA-identical sibling donors, and 45% had matched unrelated donors (UD). Conditioning regimens were predominantly reduced intensity (83%). Before transplantation, 16% o..

View full abstract